Latest news for Aeolus Pharmaceuticals (OTC:AOLS) Stock

Aeolus Pharmaceuticals Inc is a Southern California based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ACLZ

AEYE

AOBC

AOLS

AVVIY

AWLCF

AXION VENTURES INC by Axion Ventures Inc.

AXNVF

BBVA

BLKCF

BRVVF

BUDZ

CANB

CARB

CARS

CBYI

CNNXF

CNTMF

CRESY

CTIB

CURN

CYBL

DGRLY

DTCWY

EDUC

ELAN

ELIO

FDBL

FDMF

FLWPF

FOCS

GARWF

GEGP

GFSZY

GGAL

GTII

HCSG

ICTY

ITRN

IWSY

Kingfisher Sponsored American Depositary Receipt

KGFHY

KNBWY

LDSYF

LIBERTY HEALTH SCI ORD by Liberty Health Sciences Inc

LHSIF

MBUU

MCFT

MGXMF

MMLP

MMSI

MNGGF

MRSN

NCNA

NDLS

NNGPF

NNGRY

NOVA

NXGWF

NEXOPTIC TECHNOLOGY CORP by NexOptic Technology Corp

NXOPF

NXTD

OCANF

OGDCF

OLVRF

OPMG

OPMZ

ORBC

PCRFY

PFFOF

PFSW

PGNX

PNXPF

POLA

PRPH

QCAAF

QRTEB

RIGH

RSAIF

SEEK

SGTPY

SHEN

SKVKY

SQBG

SRGHY

SYAAF

TEFOF

THCBF

Stocks That Hit 52-Week Lows On Tuesday

Aeolus Pharmaceuticals Announces Positive Results From Study of AEOL 10150

Aeolus Pharmaceuticals Announces NIH Counteract Grant Award to Develop AEOL 10150 as a Treatment Against Nerve Agent Exposure

AEOLUS PHARMS INC by Aeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals Inc

CANNABIS ONE HLDGS INC by Cannabis One Holdings Inc.

CAAOF

ECCI

EEYMF

GPRC

GPXM

GTGP

MDXHF

OGES

Aeolus
Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: <a class="ticker" href="/stock/aols#PINKSHEETS">AOLS</a>), today announced preliminary results from a study of AEOL 10150 and
Neupogen(R) conducted by Christie Orschell, PhD of Indiana
University. The primary endpoint of the study was to determine
drug-drug interactions between Neupogen(R) and AEOL 10150, as well as
to monitor safety and tolerability of the two treatments given
simultaneously. Results of the study confirmed that AEOL 10150 does
not interfere with the positive effects of Neupogen(R) on the
hematopoietic, or bone marrow, syndrome of Acute Radiation Syndrome
(ARS), and the two products in combination were safe and well
tolerated.

Aeolus
Pharmaceuticals, Inc. (OTC: <a class="ticker" href="/stock/aols#OTC">AOLS</a>), today announced that NIH CounterACT has awarded
a $735,951 contract to Manisha Patel, PhD at the University of
Colorado Anschutz Medical Campus to develop AEOL 10150 as a medical
countermeasure against nerve agents, titled "Evaluation of
Neuroprotective Effects of AEOL 10150 against Chemical Threat
Agents."

Since the earthquake in Japan, radiation exposure has come to the forefront of medical developments. Workers dealing with the nuclear reactors are potentially being exposed to hazardous levels, requiring treatments for radiation poisoning.

According to the <a href="http://www.nytimes.com/2011/04/01/business/01radiation.html?_r=2&amp;ref=business">New York Times</a>, “…the drugs under development would allow people to survive doses 20 to 40 percent higher than what is now considered lethal.”

Companies involved in the development of such treatments have seen high trading volumes since the earthquake in Japan. Aeolus Pharmaceuticals (OTC: <a class="ticker" href="/stock/aols#OTC">AOLS</a>) saw trading volumes 1,000 times normal on the day following the crisis. Aeolus has a $118 million federal contract to develop a drug used to protect the lungs from radiation damage.

In emergency cases, drugs not yet approved by the Food and Drug Administration (FDA) can be issued an “emergency use authorization.” Amgen (NASDAQ: <a class="ticker" href="/stock/amgn#NASDAQ">AMGN</a>) currently has gained this approval for their drug Neupogen, a drug used to help the body create white blood cells to fight infection. The Department of Health and Human Services is planning a possible mass purchase of Neupogen or a similar generic to stockpile for emergency radiation poisoning situations.

Neupogen is only one of many drugs being developed for radiation treatment, but most drugs are two to five years from approval. Radiation treatments are difficult to test because it is unethical to expose humans to radiation for a clinical trial. These drugs have to, instead, be tested in two different animal species and have to be safe to humans in corresponding doses.

Cellerant Therapetics has been granted government funding of $153 million over five years to develop an immune system boosting drug using stem cells to help combat radiation exposure.

The most common form of exposure for the public would be from isotopes. The federal stockpile currently has approved drugs stockpiled for this, such as potassium iodide and Prussian blue.

The drugs in development would most likely not be effective in reducing long-term cancer risk from exposure to radiation.

Politics

AMGN

Radiation Treatment Developments On The Rise

Aeolus Pharmaceuticals, Inc. (AOLS) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (<a class="ticker" href="/stock/hhs#">HHS</a>), has awarded Aeolus a contract for the advanced development of AEOL 10150 as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (ARS). 
Under terms of this cost plus, fixed fee development contract, Aeolus will receive $10.4 million in the first year base period of performance and up to an additional $107.5 million in options , if exercised by BARDA, for a total contract value of up to $118 million. In addition to fully covering the cost of development of AEOL 10150 as an MCM for Lung ARS, the Company believes that the contract with BARDA will substantially cover all of the costs associated with the preclinical, chemistry, manufacturing, and controls (<a class="ticker" href="/stock/cmc#">CMC</a>) and toxicology necessary for the oncology indications, plus a large safety study in humans.

Contracts

Aeolus Awarded Contract Fully Valued at $118 Million from BARDA 

Aeolus Pharmaceuticals

Aeolus
Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: <a class="ticker" href="/stock/aols#PINKSHEETS">AOLS</a>), today announced preliminary results from a study of AEOL 10150 and
Neupogen(R) conducted by Christie Orschell, PhD of Indiana
University. The primary endpoint of the study was to determine
drug-drug interactions between Neupogen(R) and AEOL 10150, as well as
to monitor safety and tolerability of the two treatments given
simultaneously. Results of the study confirmed that AEOL 10150 does
not interfere with the positive effects of Neupogen(R) on the
hematopoietic, or bone marrow, syndrome of Acute Radiation Syndrome
(ARS), and the two products in combination were safe and well
tolerated.

Aeolus
Pharmaceuticals, Inc. (OTC: <a class="ticker" href="/stock/aols#OTC">AOLS</a>), today announced that NIH CounterACT has awarded
a $735,951 contract to Manisha Patel, PhD at the University of
Colorado Anschutz Medical Campus to develop AEOL 10150 as a medical
countermeasure against nerve agents, titled "Evaluation of
Neuroprotective Effects of AEOL 10150 against Chemical Threat
Agents."

Since the earthquake in Japan, radiation exposure has come to the forefront of medical developments. Workers dealing with the nuclear reactors are potentially being exposed to hazardous levels, requiring treatments for radiation poisoning.

According to the <a href="http://www.nytimes.com/2011/04/01/business/01radiation.html?_r=2&ref=business">New York Times</a>, “…the drugs under development would allow people to survive doses 20 to 40 percent higher than what is now considered lethal.”

Companies involved in the development of such treatments have seen high trading volumes since the earthquake in Japan. Aeolus Pharmaceuticals (OTC: <a class="ticker" href="/stock/aols#OTC">AOLS</a>) saw trading volumes 1,000 times normal on the day following the crisis. Aeolus has a $118 million federal contract to develop a drug used to protect the lungs from radiation damage.

In emergency cases, drugs not yet approved by the Food and Drug Administration (FDA) can be issued an “emergency use authorization.” Amgen (NASDAQ: <a class="ticker" href="/stock/amgn#NASDAQ">AMGN</a>) currently has gained this approval for their drug Neupogen, a drug used to help the body create white blood cells to fight infection. The Department of Health and Human Services is planning a possible mass purchase of Neupogen or a similar generic to stockpile for emergency radiation poisoning situations.

Neupogen is only one of many drugs being developed for radiation treatment, but most drugs are two to five years from approval. Radiation treatments are difficult to test because it is unethical to expose humans to radiation for a clinical trial. These drugs have to, instead, be tested in two different animal species and have to be safe to humans in corresponding doses.

Cellerant Therapetics has been granted government funding of $153 million over five years to develop an immune system boosting drug using stem cells to help combat radiation exposure.

The most common form of exposure for the public would be from isotopes. The federal stockpile currently has approved drugs stockpiled for this, such as potassium iodide and Prussian blue.

The drugs in development would most likely not be effective in reducing long-term cancer risk from exposure to radiation.

Aeolus Pharmaceuticals, Inc. (AOLS) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (<a class="ticker" href="/stock/hhs#">HHS</a>), has awarded Aeolus a contract for the advanced development of AEOL 10150 as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (ARS). 

Under terms of this cost plus, fixed fee development contract, Aeolus will receive $10.4 million in the first year base period of performance and up to an additional $107.5 million in options , if exercised by BARDA, for a total contract value of up to $118 million. In addition to fully covering the cost of development of AEOL 10150 as an MCM for Lung ARS, the Company believes that the contract with BARDA will substantially cover all of the costs associated with the preclinical, chemistry, manufacturing, and controls (<a class="ticker" href="/stock/cmc#">CMC</a>) and toxicology necessary for the oncology indications, plus a large safety study in humans.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Aeolus Pharmaceuticals

News

Latest news for Aeolus Pharmaceuticals (OTC:AOLS) Stock

Tuesday, August 20, 2019

Tuesday, November 01, 2011

Monday, October 24, 2011

Friday, April 01, 2011

Tuesday, February 15, 2011